Atezolizumab

In this video, Andrew Ciupek, PhD, discusses findings from the Alliance trial, IMpower010 and NADIM-2.

Narjust Florez (Duma), MD, discusses results from two studies presented at World Conference on Lung Cancer — IMpower010 and NADIM-2

In this video, Jia Luo, MD, discusses two presentations from International Association for the Study of Lung Cancer World Conference on Lung Cancer investigating treatments for KRAS G12C lung cancer.

Atezolizumab plus a modified docetaxel, cisplatin and 5-fluorouracilregimen is a safe and effective first-line treatment for locally advanced squamous cell anal carcinoma, according to research presented at 2022 ASCO Annual Meeting.

World Lung Cancer Day will be held Aug. 1.

The effects of atezolizumab combined with a chemotherapy regimen were beneficial in terms of pathologic outcome compared with the chemotherapy regimen alone for patients with resectable esophagogastric adenocarcinoma.

In this video, Howard S. Hochester, MD, discusses the COMMIT study comparing the anti-PD1 drug atezolizumab with atezolizumab combined with FOLFOX chemotherapy presented as part of a poster session at ASCO Annual Meeting.

CHICAGO — Adding tiragolumab, an anti-TIGIT agent, to atezolizumab and carboplatin plus etoposide did not provide more benefit compared with atezolizumab and carboplatin plus etoposide alone, according to findings from SKYSCRAPER-02 trial.

CHICAGO — Cabozantinib plus atezolizumab showed encouraging clinical activity in patients with inoperable locally advanced or metastatic urothelial carcinoma, according to data from the COSMIC-021 study.

In this edition, AYA cancer survivors are at higher risk for death due to second primary cancers; a radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer; a phase 3 trial of tiragolumab plus atezolizumab misses its co-primary endpoint; and more.